![]() |
|
||||
| Degree: | Ph.D. |
| Institution: | University of Texas at Houston |
| Period: | 1993 |
| Degree: | BSc. Pharm. |
| Institution: | University of Texas at Austin |
| Period: | 1985 |
| Position: | Professor and Distinguished University Scholar |
| Dr. Wasan was one of the recipients of the 1993 American Association of Pharmaceutical Scientists (AAPS) Graduate Student Awards for Excellence in Graduate Research in Drug Delivery, the 2001 AAPS New Investigator Award/Grant in Pharmaceutics and Pharmaceutics Technologies, the 2002 Association of Faculties of Pharmacy of Canada New Investigator Research Award and recently was named an AAPS fellow in 2006. In addition, Dr. Wasan was awarded a Canadian Institutes of Health Research University-Industry Research Chair in Pharmaceutical Development (2003-2008), was named a University Distinguished Scholar in April 2004 received the 2007 AAPS Award for Outstanding Research in Lipid-Based Drug Delivery and the 2008 AFPC-Pfizer Research Career Award. In April 2009 Dr. Wasan was named CIHR/iCo Therapeutics Research Chair in Drug Delivery for Neglected Global Diseases. Currently Dr. Wasan’s research is supported by several grants from The Canadian Institutes of Health Research, several pharmaceutical companies and the National Cancer Institute of Canada-Clinical Trials Group. |
The plasma lipoprotein distribution of potential drug candidates is not commonly studied. For some hydrophobic drug candidates, attainment of similar plasma free drug levels has not been associated with uniform production of pharmacological activity in different animal species. It is well known that plasma lipoprotein lipid profiles vary considerably between different animal species. In addition, human disease states can significantly influence plasma lipoprotein profiles resulting in altered drug therapeutic outcomes. A plausible explanation for these findings may be a result of lipoprotein drug transport within the systemic circulation. Elucidation of the mechanisms that dictate the lipoprotein binding of drugs may yield valuable insight into the factors governing the pharmacological activity and potential toxicity of these compounds. Furthermore, utilizing these factors to target compounds specifically to one lipoprotein subclass over another could, potentially, improve the drug’s efficacy and safety.
Over the past 14 years, my laboratory has published a number of studies and has established the experimental methodologies necessary to justify the importance of investigating the role of lipids and lipoproteins in modifying the biological activity of water-insoluble drugs. With these research tools in place, my laboratory has now demonstrated and provided the potential mechanisms by which water-insoluble drugs interact with lipids and lipoproteins and how these interactions impact on the absorption, distribution, efficacy, toxicity and metabolism of such compounds.
In the larger perspective, these studies have increased the understanding of the mechanisms involved in serum distribution of hydrophobic drugs. In contrast to albumin protein binding, lipoprotein binding of drugs is often overlooked and so the role of lipoproteins as possible intravascular carriers for hydrophobic compounds and their involvement in modifying the biological effects of drugs is a novel and pharmaceutically important discovery. Recently, the FDA (Spring 2002) has suggested that lipoprotein-drug distribution studies should be considered as part of any new IND application that contains a hydrophobic compound. In addition many pharmaceutical companies screen hydrophobic compounds for plasma lipoprotein distribution.
The Wasan lab is actively engaged in the UBC-Neglected Global Diseases Initiative and recently has published work in this area. As a publicly funded institution, the University of British Columbia believes that universities have a fundamental commitment and moral responsibility to advance the public good. In keeping with this, the Global Access Initiative (www.uilo.ubc.ca/about/initiatives/global.html) has enabled UBC to harness the economic potential of University innovations to ensure their development, while at the same time enhancing their social benefit by ensuring fair and affordable access for developing countries. The opportunity exists to harness Canada’s existing research resources and well-respected reputation in international aid to fulfill a moral commitment to the developing world, to win technical leadership in a field of growing scientific and commercial importance, and to protect the health of all populations.
The Neglected Global Diseases Initiative (NGDI; www.ngdi-ubc.com) will bring together the technical expertise and perspectives of a variety of disciplines at UBC – including bench science, pharmaceutical and health research, business, social policy, and law – to investigate truly innovative and effective ways of breaking down the present barriers to success in producing affordable, life-sustaining medicines for the treatment of the world’s most neglected diseases.
The Wasan Laboratory is currently conducting research in the following areas:
ollectively our research in this area has been cited over 350 times in the past decade. A number of key papers with several compounds (i.e. Amphotericin B, Cyclosporine, Halofantrine, Nystatin, E5564, Clozapine) have been published demonstrating the importance of drug association with plasma lipoproteins.Several key papers are highlighted below
*For a full list of Publications, visit the PubMed Website |
« Back